Growth hormone (GH) secretion and response to GH therapy after total body irradiation and haematopoietic stem cell transplantation during childhood.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

In January 1997 the researchers introduced a protocol for the treatment with GH of children with impaired growth after unfractionated total body irradiation (TBI).

This study is an evaluation of that protocol.

Who Took Part

According to the abstract, 2005, patients were involved.

The age groups tagged for this paper are children and teenagers, both men and women.

Between January 1997 and July 2005, 66 patients (48 male) treated for haematological malignancies had at least two years of disease-free survival after TBI-based conditioning for stem cell transplantation (SCT).

How the Study Was Run

The main outcome measure was the effect of GH therapy on height standard deviation scores (SDS) after onset of GH therapy, estimated by random-effect modelling with corrections for sex, age at time of SCT and puberty (data analysed on intention-to-treat basis).

What Was Measured

Topics PubMed links to this paper include Body Height, Carcinoma, Papillary, Growth Disorders, Growth Hormone, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation and Hormone Replacement Therapy.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 2005, patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.